Efficacy and safety of short-term sensor-augmented insulin-pump therapy for poorly controlled patients with type 1 diabetes mellitus
10.3760/cma.j.issn.1671-7368.2016.02.011
- VernacularTitle:血糖控制不佳的1型糖尿病患者短期应用实时动态胰岛素泵的疗效及安全性观察
- Author:
Chunhong SHI
;
Lisha ZHANG
;
Ran BAI
;
Dan LIU
;
Yongbo WANG
;
Hao WANG
;
Yu YANG
;
Xueyang ZHANG
;
Yangyang JI
;
Jianling DU
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 1;
Insulin infusion systems;
Continuous glucose monitoring;
Treatment outcome
- From:
Chinese Journal of General Practitioners
2016;(2):118-122
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of short-term sensor-augmented insulin-pump (SAP) therapy for poorly controlled patients with type 1 diabetes mellitus (T1DM).Methods Sixty T1DM patients with glycosylated hemoglobin (HbA1c)>9.0% were randomly assigned to 2 groups treated with SAP or multiple daily insulin injection ( MDI) for 6 days, then all patients converted to MDI therapy. Results Compared with MDI group and before therapy, the mean blood glucose concentration ( MBG) , SD of blood glucose, mean amplitude of glycemic excursion ( MAGE) and 24-h area under curve at 10.0 ( AUC10.0 ) levels in SAP group significantly decreased after 6-day therapy ( compared with MDI group:t=1.761,P=0.028, t=2.569,P=0.037, t=2.712,P=0.020, t=2.985,P=0.014, compared with before therapy:t=3.128,P=0.006, t=2.689,P=0.024, t=2.966,P=0.013, t=3.076,P=0.009);while there was no difference in 24-h area under curve at 3.9 (AUC3.9) between groups (P>0.05).After 1 month follow-up HbA1c levels decreased in SAP group (t=2.344,P=0.023) and were significantly lower than those in MDI group (t=1.844, P=0.035).There was no difference in daily insulin dosage, fasting C peptide (FCP) and postprandial 2h C peptide (2hCP) between two groups (P>0.05).Age (t=2.125, P=0.012) and SAP therapy (t=3.376, P=0.009) were independently correlated with the HbA1c after 1 month.Conclusion Short-term SAP therapy is effective and safe for poorly controlled T1DM patients with rapid glucose lowering and glycemic excursions reduction.
